NEWS FLASH:
Scientists Use Chemical Biology Approach to Assist Cardiac Regeneration


Quicklinks:
Job Postings
TMAU Testing

 

Read the 2011 HBRI Winter Newsletter

 

 

 

Scientists Use Stem Cells to Heal
Damaged Heart Tissue

 

FIGURE Discovering new medications for cardiovasular disease. Work of the Human BioMolecular Research Institute in collaboration with the Sanford-Burnham Medical Research Institute; John Cashman, Ph.D. and Mark Mercola, Ph.D., respectively.

"Rat neonatal cardiomyocytes stained for cell membrane (green) and alpha actinin (red). CyteSeer from Vala Sciences was used to identify sitesof alpha-actinin fluorescence.

Images by Pat McDonough, Ph.D., at Vala Sciences and Fabio Cerignoli, Ph.D., Sanford-Burnham Medical Research Institute.

 


Scientists at HBRI have developed approaches that combine stem cell and chemical biology technologies to stimulate cardiogenesis in stem cells and eventually contribute to the development of drugs for regenerating heart muscle tissue.

 

The combination of medicinal chemical and stem cell biology is unprecedented in the field of cardiovascular disease research, and represents an exciting new approach to discover therapies for a disease that is the number one killer of adults in the United States, an done that affects millions of people worldwide.

 

CLICK HERE to read the full press release.

 



Donate to HUMAN BIOMOLECULAR RESEARCH INSTITUTE with the Capital One No Hassle Giving Site.

Capital One cardholders can donate with no transaction fee.

The Human BioMolecular Research Institute (HBRI) is a 501(c)3 tax-exempt non-profit research institute doing basic research for the public good. HBRI was founded in December of 1997.  The institute is located in the heart of biotech beach in a state-of-the-art 6,700 sq. ft. facility.

The research programs at HBRI are focused on unlocking biological and chemical principles related to diseases of the human brain.  Included in the areas of study are: Alzheimer’s disease and related neurodegenerative disorders, Parkinson’s disease, ALS, depression, neuroprotection, regenerative medicine, cardiovascular disease, cancer, drug and alcohol abuse, pain and smoking cessation.  The institute conducts fundamental studies of central nervous system disorders and translates findings into new drug development to address human illness.  In addition, the institute promotes scientific learning through community service and public access by disseminating information and sharing research with collaborators, colleagues and the public.

"Because Every Brain is not the Same"